Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Your doctor may arrange investigations including a full blood count, serum folate levels, and in some cases, anti-intrinsic factor antibodies if pernicious anaemia hasn't been previously confirmed
Watson closely monitors how each patient responds to either treatment, noting their weight loss progress, appetite control, and overall health improvements
Unexplained fatigue or weakness: While some fatigue is expected during weight loss, severe or progressive weakness, especially if accompanied by other symptoms, should be evaluated to rule out electrolyte imbalances, thyroid dysfunction, or other medical conditions
Use of SYNJARDY for this indication is supported by evidence from a 26-week double-blind, placebo-controlled clinical trial of empagliflozin, with a double-blind active treatment safety extension period of up to 52 weeks in 157 pediatric patients aged 10 to 17 years with type 2 diabetes mellitus and a pediatric pharmacokinetic study [see Clinical Pharmacology (12.3) and Clinical Studies (14.2)]
